文献速递胃肠外科围术期管理与 ERAS

ST03试验中胃癌及胃食管交界癌围手术期化疗的手术质量保证

Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.
PubMed 文献 · Br J Surg · 2019-07-03

ST03试验比较围手术期ECX方案联合或不联合贝伐珠单抗治疗胃癌及胃食管交界癌,两组生存无差异。本研究回顾性审查手术和病理报告表,评估手术对方案标准的依从性、围手术期并发症和死亡率以及最终病理分期。

要点

  • ST03试验中手术实施符合方案规定的手术标准。

核心结论

  • 在ST03试验中,手术实施符合方案规定的手术标准。

研究设计与样本

  • 对ST03随机试验中所有接受治疗患者的手术和病理临床报告表进行回顾性审查,以确定对手术方案的依从性、围手术期并发症和死亡率以及最终组织病理学分期。

临床怎么用

  • 该试验的手术质量保证数据可为胃癌及胃食管交界癌围手术期治疗中的手术标准执行提供参考。
  • 需关注胃食管切除术后吻合口漏风险,尤其是在联合贝伐珠单抗治疗时。
  • 淋巴结检出数和R1切除率是评估手术质量的重要指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The UK Medical Research Council ST03 trial compared perioperative epirubicin, cisplatin and capecitabine (ECX) chemotherapy with or without bevacizumab (B) in gastric and oesophagogastric junctional cancer. No difference in survival was noted between the arms of the trial. The present study reviewed the standards and performance of surgery in the context of the protocol-specified surgical criteria. METHODS: Surgical and pathological clinical report forms were reviewed to determine adherence to the surgical protocols, perioperative morbidity and mortality, and final histopathological stage for all patients treated in the study. RESULTS: Of 1063 patients randomized, 895 (84·2 per cent) underwent resection; surgical details were available for 880 (98·3 per cent). Postoperative assessment data were available for 873 patients; complications occurred in 458 (52·5 per cent) overall, of whom 71 (8·1 per cent) developed complications deemed to be life-threatening by the responsible clinician. The most common complications were respiratory (211 patients, 24·2 per cent). The anastomotic leak rate was 118 of 873 (13·5 per cent) overall; among those who underwent oesophagogastrectomy, the rate was higher in the group receiving ECX-B (23·6 per cent versus 9·9 per cent in the ECX group). Pathological assessment data were available for 845 patients. At least 15 nodes were removed in 82·5 per cent of resections and the median lymph node harvest was 24 (i.q.r. 17-34). Twenty-five or more nodes were removed in 49·0 per cent of patients. Histopathologically, the R1 rate was 24·9 per cent (208 of 834 patients). An R1 resection was more common for proximal tumours. CONCLUSION: In the ST03 trial, the performance of surgery met the protocol-stipulated criteria. Registration number: NCT00450203 ( http://www.clinicaltrials.gov).

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Allum WH, Smyth EC, Blazeby JM, et al. Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction. Br J Surg. 2019. PMID: 31268180. doi:10.1002/bjs.11184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。